News

FDA accepts Palvella's QTORIN rapamycin NDA with Priority Review for rare skin disease

What's the deal? Palvella Therapeutics announced on 28 October 2026 that the US FDA has accepted its New Drug Application (NDA) for QTORIN rapamycin (3.9% rapamycin anhydrous gel) and granted Priority Review, setting a PDUFA target action date of 28 February 2027 for a decision. QTORIN rapamycin is being developed to treat microcystic lymphatic malformations (microcystic LMs) - a rare, lifelong disorder of malformed lymphatic vessels that causes painful, fluid-filled skin lesions, estimated to affect more than 30,000 diagnosed children and adults in the US. It could become the first FDA-approved therapy for the disease.

Why it matters: Rapamycin (sirolimus) is an established immunosuppressant that blocks the mTOR growth pathway; delivered as a topical gel, QTORIN aims to shrink lesions locally while keeping drug levels in the blood negligible (measured below 2 ng/mL at all time points in the pivotal trial). The filing is supported by the Phase 3 SELVA study, which hit all six prespecified efficacy endpoints (all p<0.001), with 95% of participants aged 6 and older who completed the efficacy evaluation showing improvement on the primary skin-lesion measure. The programme already holds FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. Palvella is preparing for a potential US launch in the first half of 2027, subject to approval.

Read more: BioSpace / Palvella Therapeutics, 28 October 2026

More top stories